Posters
Comparison of IPL with lid-squeezing group and IPL only treatment group
Poster Details
First Author: K.Shin SOUTH KOREA
Co Author(s): D. Lim C. Yang C. Moon B. Kim T. Chung
Abstract Details
Purpose:
To evaluate the effect of IPL treatment for Meibomian gland dysfunction (MGD) and the effect of lid squeezing with IPL treatment.
Setting:
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Methods:
This is a randomized prospective study. Patients (232 eyes of 116 subjects) with MGD were randomly divided into two groups. Patients in group1 received 2cycle of IPL treatment using M22®(Lumenis, Dreieich, Germany) with lid squeezing for 4 weeks; patient in group2 received IPL treatment only. Ocular Surface Disease Index(OSDI), and Meibomian gland expressibility(MGE), Meibomian gland quality(MGQ) score were collected. Lipid layer thickness measured by Keratograph ®5M(Oculus, Wetzlar, Germany). To evaluate ocular surface, we measured tear break-up time(BUT) and fluorescein corneal staining score(Oxford scale). We collected data on baseline, 4weeks. Independent t-test was utilized to prove differences between two groups.
Results:
Dry eye symptom (OSDI), Meibomian gland function (MGE, MGQ), and fluorecein corneal staining score(Oxford scale)of patients were significantly improved after the treatment (p < 0.05, respectively). There was no statistically significant difference between the two groups in Oxford scale(1.86±0.245, 1.46±0.242 p=0.241), MGE(0.33±0.068, 0.26±0.091 p=0.633), and MGQ (4.09±0.558, 4.96±0.474 p=0.465) at baseline, 4 weeks respectively. No significant adverse event occurred during study period.
Conclusions:
IPL treatment with M22® is an effective and safe treatment for MGD. But lid squeezing had no significant additional effect on IPL treatment. But our study was performed only 2 sessions, although 4 sessions were recommended as standard. Further studies would be necessary to evaluate the effect of lid squeezing on IPL treatment.
Financial Disclosure:
None